Hammerson In Talks On Terms Of Possible Disposal Of Retail Parks Portfolio

Hammerson plc (HMSO.L) confirmed the Group is in talks on terms of a possible disposal of its retail parks portfolio to Brookfield. The Group made the announcement as a response to recent press speculation. The company noted that there can be no certainty that a deal will take place or the terms on which any transaction may occur.

Hammerson plc said it continues to make asset disposals in liquid markets to further strengthen the balance sheet, with gross proceeds of 73 million pounds achieved to date in 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT